American Society of Hirudotherapy

Safety Algorithm Cards

Printable clinician-facing decision cards. Aeromonas management, bleeding management, transfusion thresholds. Versioned + reviewer-stamped.

Last Updated: May 27, 2026Reviewed by: Andrei Dokukin, MD
Clinician reference — institutional protocolWithin K040187 clinical-use context

Three printable decision cards for clinicians working with medicinal leech therapy. Each card is versioned, dated, and reviewer-stamped. Print directly to a single page from your browser.

Cards are educational references. They do not substitute for institutional protocol, infectious disease consult, hematology consult, or active clinical supervision. Verify against your local institution's policies before clinical use.

Full Aeromonas management guidance → · All safety protocols

Aeromonas Management Algorithm

v2.0.0 (2026-05-27)Next review: 2026-11-27

Suspected or confirmed Aeromonas infection complicating medicinal leech therapy. Adult inpatients and outpatients. Pediatric: consult pediatric ID.

Reviewed by: Andrei Dokukin, MD — ASH Editorial Board

  1. Suspect Aeromonas infection

    Within 4 weeks of leech therapy: erythema, pain, swelling, purulent drainage, fever, or any soft-tissue infection sign at or near a bite site. Aeromonas is the dominant pathogen because Aeromonas veronii / hydrophila colonise the leech gut.

    • Onset ranges from within 24 hours of leech application to 10 days or more, with delayed cases reported up to 26 days after the start of therapy
    • Site adjacent to leech application most common; distant fasciitis possible
    • Concomitant flap failure is a red flag
  2. Workup

    Blood cultures ×2, wound culture, CBC, CRP/procalcitonin if available. Imaging (US/CT) if fasciitis or abscess suspected.

    • Notify microbiology: "history of medicinal leech therapy — query Aeromonas"
    • Aeromonas grows on standard blood agar but may be missed if not flagged
  3. Initiate empiric antibiotic

    Cover Aeromonas spp. while awaiting culture. First-line: ciprofloxacin 750 mg PO BID or 400 mg IV BID. Alternatives: TMP-SMX, third-generation cephalosporin + fluoroquinolone, or doxycycline.

    • AVOID empiric ampicillin / amoxicillin (Aeromonas typically resistant)
    • AVOID first-generation cephalosporins
    • Adjust based on culture + susceptibility at 48-72 hours
  4. Source control

    Drain abscess if present. Debride necrotic tissue. For flap salvage, consult plastic surgery for re-exploration if salvage still viable.

  5. Escalate

    If sepsis, necrotizing fasciitis, or rapid progression: ICU, broad-spectrum coverage (piperacillin-tazobactam + ciprofloxacin), urgent surgical consult, infectious disease consult.

    • Necrotizing soft-tissue infection mortality is high; do not delay surgical exploration
    • Reduce immunosuppression where safely possible
  6. Document + report

    Document leech batch, supplier, hospital protocol followed, antibiotic prophylaxis history. Report to institutional infection-control and to MAUDE if device-related adverse event.

References

  1. Wilmer A et al. 2013 — leech-water antibiotic surveillance (PMID 23417901)
  2. Beka L et al. 2018 — Aeromonas ciprofloxacin resistance from leech (PMID 30042201)
  3. Kruer RM et al. 2014 — MLT antibiotic prophylaxis multicenter (PMID 25423029)
  4. Karasartova D et al. 2025 — microbiota dynamics in hirudotherapy infections (PMID 40284753)
American Society of Hirudotherapy · hirudotherapysociety.org · Educational reference, not medical advice. Verify with institutional protocol and current evidence.

Bleeding Management + Transfusion Threshold Algorithm

v2.0.0 (2026-05-27)Next review: 2026-11-27

Cumulative blood loss assessment during leech therapy. Iron supplementation timing. Restrictive transfusion threshold per AABB 2023 guidelines.

Reviewed by: Andrei Dokukin, MD — ASH Editorial Board

  1. Assess baseline + ongoing bleeding

    Each detached leech produces 6-24 hours of low-grade bleeding (10-50 mL per site). With multiple leeches over multiple sessions, cumulative blood loss is clinically significant.

    • Baseline Hgb/Hct + iron studies + reticulocyte count BEFORE initiation
    • Daily Hgb monitoring during active therapy
    • Measure total session blood loss; do not underestimate (a saturated 30 × 30 cm abdominal pad ≈ 100 mL)
  2. Iron supplementation

    Initiate oral iron at therapy start: ferrous sulfate 325 mg PO TID or equivalent. IV iron (iron sucrose, ferric carboxymaltose) if oral not tolerated.

  3. Transfusion threshold

    Restrictive transfusion strategy: transfuse if Hgb < 7 g/dL, OR Hgb < 8 g/dL with symptoms (orthostasis, dyspnea, tachycardia, ischemia). In actively bleeding microsurgery flap patient, lower threshold (7.5-8 g/dL) is reasonable.

    • AABB 2023 guidelines support 7 g/dL restrictive threshold for most hospitalised adults
    • Anticipate need for type & screen BEFORE Hgb drop is critical
  4. Stop therapy + hemostasis if bleeding excessive

    If a bite site bleeds >24h after detachment, OR pulsatile: apply pressure 10 minutes. If still bleeding, topical hemostatic (gelfoam, surgicel, thrombin), suture if mechanical control needed.

    • Excessive bleeding from a single bite is RARE; if seen, check coagulation panel
    • Consider undiagnosed coagulopathy (vWD, factor deficiency, anticoagulant use)
  5. Escalate

    If hemorrhagic shock, transfusion failure, or coagulopathy: massive transfusion protocol, hematology consult, ICU. Document leech sessions in the bleeding history.

References

  1. Carson JL et al. 2023 AABB transfusion threshold guidelines (PMID 37824153)
  2. Whitaker IS et al. 2012 — microsurgical leech flap salvage systematic review (PMID 22407551)
American Society of Hirudotherapy · hirudotherapysociety.org · Educational reference, not medical advice. Verify with institutional protocol and current evidence.

Printing tips

  • Use Chrome / Edge print preview for best results (Cmd/Ctrl + P).
  • Set "Background graphics" ON to preserve severity color coding.
  • Each algorithm card fits on a single landscape page.
  • Page header / footer can be turned off for clean print.

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.